Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (427)	6/25/1999 8:51:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 579

[ parking, ignore ] the oldest description of the OSIP/Pfizer deal that I've been able to find....... In April 1986, Pfizer and the Company entered into a collaborative research agreement and several other related agreements. During the first five years of the collaboration, the Company and Pfizer focused principally on understanding the molecular biology of oncogenes. In 1991, Pfizer and the Company renewed the collaboration for a second five-year term and expanded the resources and scope of the collaboration to focus on the discovery and development of cancer therapeutic products based on mechanisms-of-action that target oncogenes and anti-oncogenes. Oncogenes play a key role in the conversion of normal cells to a cancerous state and can cause cancer when they mutate or over express. Anti-oncogenes, or tumor suppressor genes, encode proteins that generally function to block the proliferative growth of particular cell types. A loss of function of certain tumor suppressor genes can result in uncontrolled cell growth. Effective April 1, 1996, the Company and Pfizer renewed their collaboration for a new five-year term by entering into new collaborative research and license agreements. Currently, the Company's collaboration with Pfizer focuses on discovering compounds that act upon various target proteins involved in cancer. The Company's screening program has resulted in the identification of a proprietary lead compound, CP-358,774, that inhibits the activity of the Epidermal Growth Factor Receptor, a protein associated with a number of major cancers. Pfizer is conducting Phase I safety and toxicity studies in the United States on this compound. The continued development of this compound depends on several factors outside the control of the Company, including the amount and timing of resources devoted by Pfizer, successful completion of safety and toxicity studies and successful optimization of the compound. There can be no assurance that a drug will result from this program. All patent rights and patentable inventions derived from the research under this collaboration are owned jointly by the Company and Pfizer. The Company has granted Pfizer an exclusive, worldwide license to make, use, and sell the therapeutic products resulting from this collaboration in exchange for royalty payments. This license terminates on the date of the last to expire of the Company's relevant patent rights.